Zymeworks EBITDA 2016-2022 | ZYME
Zymeworks ebitda from 2016 to 2022. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Zymeworks Annual EBITDA
(Millions of US $) |
| 2021 |
$-206 |
| 2020 |
$-177 |
| 2019 |
$-144 |
| 2018 |
$-30 |
| 2017 |
$-6 |
| 2016 |
$-37 |
| 2015 |
$-19 |
Zymeworks Quarterly EBITDA
(Millions of US $) |
| 2022-06-30 |
$-64 |
| 2022-03-31 |
$-67 |
| 2021-12-31 |
$-39 |
| 2021-09-30 |
$-58 |
| 2021-06-30 |
$-66 |
| 2021-03-31 |
$-42 |
| 2020-12-31 |
$-35 |
| 2020-09-30 |
$-69 |
| 2020-06-30 |
$-40 |
| 2020-03-31 |
$-33 |
| 2019-12-31 |
$-71 |
| 2019-09-30 |
$-32 |
| 2019-06-30 |
$-28 |
| 2019-03-31 |
$-13 |
| 2018-12-31 |
$9 |
| 2018-09-30 |
$-19 |
| 2018-06-30 |
$-1 |
| 2018-03-31 |
$-19 |
| 2017-12-31 |
$34 |
| 2017-09-30 |
$-16 |
| 2017-06-30 |
$-9 |
| 2017-03-31 |
$-16 |
| 2016-12-31 |
$-10 |
| 2016-09-30 |
$-11 |
| 2016-06-30 |
$-6 |
| 2016-03-31 |
$-10 |
| 2015-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.614B |
$0.027B |
|
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
|
